A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy, including increased age, decreased contrast nephropathy in cardiac angiography.
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Background. Contrast nephropathy (CN) is a common cause congestive heart failure [4] . It is important to note that of renal dysfunction after cardiac angiography. Recently, N-acethese risk factors are highly prevalent among patients tylcysteine (NAC) has been found to reduce the risk of CN requiring interventional cardiac procedures. [5, 6] .
after CT imaging with contrast enhancement. The purpose of the current study was to evaluate the efficacy of NAC for the The precise physiological insult underlying contrast prevention of CN in the setting of cardiac angiography.
nephropathy is unclear and may well involve the interMethods. Eligible patients were those undergoing cardiac play of several pathogenic factors. These may include vasoangiography with serum creatinine Ͼ1.7 mg/dL. Patients were constrictive forces [7] resulting in medullary ischemia [8] , randomized to one of two groups: Group 1, IV hydration and decreased production of local prostaglandin-mediated NAC, 1200 mg one hour before angiography, and a second dose 3 hours after; Group 2, IV hydration and placebo. CN was vasodilatation [7] , a direct effect on renal tubular cells defined as an increase of 0.5 mg/dL in serum creatinine.
[9], and damage caused by oxygen radicals [10, 11] . SevResults. Seventy-nine patients completed the study. There eral drug interventions based on one or more of these were no significant differences between the groups in baseline mechanisms have been tested in trials for prophylaxis characteristics, duration of angiography, mean volume of dye against the development of renal dysfunction. Among infused or mean IV hydration. Contrast nephropathy developed in 24.0% of subjects, 26.3% NAC, and 22.0% placebo (P ϭ NS). 27 .8% placebo; P ϭ 0.09). The independent predictors of CN [18] . Unfortunately, studies have generated few resoundrisk were diabetes mellitus and preexisting chronic renal insufficiency.
ingly positive results. Therefore, these treatments are Conclusions. NAC was not effective for the prevention of not widely utilized. At present, only intravenous hydra-CN after cardiac angiography. tion and avoidance of nephrotoxic drugs are recognized as methods to decrease the incidence of contrast nephropathy [16] . Contrast nephropathy is generally defined as acute reBased on the possible role of oxidative damage in nal failure occurring within 48 hours of exposure to intrathe kidney following contrast administration, Tepel et al venous radiographic contrast that is not attributable to postulated that the antioxidant N-acetylcysteine (NAC) other causes [1] . Although generally mild, it can occaprevents renal dysfunction. They found that the incisionally result in the need for dialysis treatment, extended dence of contrast nephropathy following computed tohospital stays and increased morbidity and mortality [2, 3] . mography (CT) in patients with chronic renal insuffiThere are well known risk factors for the development of ciency was greatly reduced with NAC [19] . A significant proportion of contrast nephropathy cases in the hospital setting occurs after cardiac angiography. We performed sufficiency receiving contrast media during cardiac angiography procedures. livedo reticularis or eosinophilia, known prior insensitivity to acetylcysteine, severe asthma, breast feeding women, severe peptic ulcer disease, or respiratory detify those with a prior history of diabetes mellitus (DM), pression. Patients were excluded also if serum creatinine hypertension, chronic heart failure (CHF) and identificameasurements varied by more than 15% in the three tion of medications being taken. Other pertinent data days prior to angiography. Women of child bearing pocollected were patient's weight, probable cause of the tential not using an approved method of contraception patient's underlying renal insufficiency, indication for were not enrolled. The study protocol and informed concardiac catheterization, blood pressure, record of any dye sent were approved by the hospital's Institutional Reexposure over the preceding four weeks, and laboratory view Board. data (comprehensive metabolic profile, liver function tests, complete blood count, urinalysis, and serum creatiStudy design nine for the week prior to catheterization). Following Randomization was performed using a computer gencardiac catheterization, pertinent data recorded included erated randomization list by the research pharmacy. Eliany side effect(s) due to study drug, blood urea nitrogen gible patients were randomized on a 1:1 basis to one of (BUN), and serum creatinine immediately after cathethe two following arms: (1) Group 1, N-Acetylcysteine terization, at 48 hours and 144 hours following catheter-(NAC) plus conventional therapy; (2) Group 2, placebo ization, total volume of contrast administered, total IV plus conventional therapy.
hydration administered, and a record of the type of cathConventional therapy consisted of hydration with 1.0 eterization procedure performed. mL/kg/h of 0.45% saline for up to 12 hours prior to contrast administration and continuing for up to 12 hours after Statistical analysis contrast administration. The actual rate and duration of Contrast nephropathy was defined as an increase in IV hydration was at the discretion of the nephrologist or serum creatinine of 0.5 mg/dL at 48 hours after angiogracardiologist, who were permitted to modify the regimen phy. Differences between the groups involving continudepending on the clinical status of the patient. Only low ous variables were analyzed using the Student unpaired osmolality nonionic contrast media was used Omnipat tests. For discrete variables analysis was performed que (iohexol; Amersham Health Inc., Princeton, NY, using Fisher's Exact Test. Multivariate testing was con-USA). The dose of NAC used for this study was 1200 mg ducted by logistic regression. All results are presented as orally, administered one hour prior to and three hours mean Ϯ standard deviation. Statistical significance was following cardiac catheterization (total 2400 mg).
considered to be P values of less than 0.05. Study drug was prepared as a mixture of 6 mL NAC 20% solution with 6 mL of orange juice. The juice was RESULTS added to mask the sulfurous odor of NAC, as previously described [20] . A series of "taste tests" were conEighty-one subjects were enrolled, and 79 were included ducted to ensure blinding. Placebo was simply 12 mL of in the final analysis. Two patients were lost to follow-up orange juice.
because of immediate hospital discharge after cardiac angiography and failure to have subsequent study blood Data collection work performed. Patient characteristics are presented in Demographic information was gathered at baseline, in- Table 1 . There were no significant differences between the groups at baseline in any measured parameter. The cluding age, gender, ethnicity, a review of systems to iden- Nineteen subjects had an initial serum creatinine greater indication for coronary angiography was an acute corothan 2.5 mg/dL. Acute renal failure developed in 5 of nary syndrome in 15 of 79 patients (19.0%), chronic 12 (41.7%) of these subjects in the placebo group and 3 stable angina or an abnormal stress test 15 of 79 (19.0%), of 7 (42.8%) in the NAC group (P ϭ NS). A measurecongestive heart failure 6 of 79 (7.6%), combined factors ment of serum creatinine was made immediately post-21 of 79 (26.6%), preoperative evaluation 5 of 79 (6.3%), angiography to determine if NAC had any direct effect other 5 of 79 (6.3%), and not clear 12 of 79 (15.2%).
on the assay. In the placebo group the mean serum creatiThere were no significant differences between the groups nine was 2.1 mg/dL pre-procedure and 2.2 mg/dL immeon the indication for study.
diately afterwards (P ϭ NS). In the NAC group the The mean duration of cardiac angiography was 46.3 Ϯ pre-procedure serum creatinine was 2.1 mg/dL and was 24.2 minutes. There were no significant differences beunchanged afterwards (P ϭ NS between the groups). tween the groups in mean duration, mean volume of There were no adverse events noted after treatment with infused dye or mean total intravenous hydration admin-NAC administration. istered (Table 2) . Acute renal failure, defined as an inBy univariate analysis, predictors of the development crease in serum creatinine of 0.5 mg/dL, occurred in 19 of acute renal failure post-angiography were the presof 79 patients (24.0%). An increase of serum creatinine ence of diabetes mellitus, an elevated baseline serum Ͼ1.0 mg/dL was found in 5 of 79 patients (6.3%), and creatinine and elevated immediate pre-procedure sysan increase of greater than 2.0 mg/dL in 2 of 79 (2.4%).
tolic blood pressure (Table 3) . Importantly, neither volBoth of these latter patients required temporary hemodiume of administered contrast dye nor total volume of alysis support.
intravenous hydration were important risk predictors. In There was no significant difference between the rate addition, although elevated systolic blood pressure was of renal failure in the placebo (9 of 41; 22.0%) compared a predictor of risk, a history of hypertension by itself to the NAC (10 of 38; 26.3%; P ϭ NS) study groups was not. Both diabetes mellitus and elevated serum cre- (Figs. 1 and 2 ). Among patients with diabetes mellitus, atinine at baseline remained independent predictors of acute renal failure risk by multivariate analysis. there was a non-significant trend toward an increased DISCUSSION while our study protocol administered the drug at 1200 mg one hour prior to the procedure and then three hours The objective of this study was to determine whether afterwards. It would seem unlikely that this difference the finding of Tepel et al's study, that is, NAC prevents in administration schedule would explain the absence of contrast nephropathy in patients undergoing CT imaging NAC efficacy in our study. Orally administered NAC [19] , could be extended to include patients undergoing perleads to peak serum levels in approximately one hour, cutaneous coronary angiography. These patients as well and the elimination half-life is 2.1 hours [21] . It is unas those undergoing other interventional radiographic likely, therefore, that administration on the day prior to procedures are becoming the major source of contrast exposure would be effective. Our administration schedmediated nephropathy in hospitalized patients [5, 6] , and ule was more rational from the standpoint of pharmacothe discovery of a simple and effective means by which kinetics. However, since it cannot be excluded that a to prevent this complication would be widely adopted.
metabolite of NAC might have antioxidant or other faUnfortunately, our present study fails to demonstrate vorable properties, it is possible that earlier administrathat oral NAC prevents acute renal failure following tion could have been helpful in Tepel et al's study. cardiac angiography.
It is possible that the difference in study results ocAs discussed later in this article, both the pathogenesis curred by chance. Our study may have failed to detect of contrast-induced renal dysfunction and the mechaa difference in study groups that was truly present (Type nisms of potential NAC protection are poorly under-II statistical error) or Tepel et al may have found a stood. Therefore, they do not provide a strong foundadifference in study groups that did not represent a true tion upon which to explain the difference in the outcomes drug effect (Type I error). The magnitude of effect found of these two studies. However, discussion of the proceby Tepel was dramatic, a reduction of contrast nephropadural, demographic, pharmacokinetic, and probable difthy from 22% in the placebo group to 2% in the NAC ferences between the two studies may prove to be useful group (greater than 90% risk reduction). Such a large in formulating further studies on the possible protective treatment effect would make it quite unlikely that chance effects of NAC.
alone would explain the difference in efficacy found in The definition of renal failure was the same in both the studies. Another possible explanation for the lack studies: an increase in serum creatinine of 0.5 mg/dL at of effect for NAC might relate to subtle differences be-48 hours post-contrast exposure. There were differences tween groups in saline diuresis or in diuretic use. Since between the studies, however, that might help explain we do not have data on actual urine output post-saline the discrepant results. First, we studied contrast use not infusion, it is possible that certain predisposed patients in the setting of CT imaging, but instead in cardiac angidid not have a satisfactory diuresis. The likelihood of ography. As a result, our patient population was slightly this is diminished by the fact that on average patients older (by ϳ4 years) and had a greater proportion of received more than the prescribed saline infusion volume men (66.7 vs. 56.6%) and diabetics (48.1 vs. 32.5%). The and that there were no significant difference in infusion baseline serum creatinine was similar in the two studies volume between the placebo and NAC groups. In addi-(2.3 vs. 2.4 mg/dL). Intravenous hydration, which may tion, while there were no significant differences between reduce the risk of contrast nephropathy, was used in diuretic use in the two groups, we cannot exclude the both studies. In the study by Tepel et al it appears that possibility that use of diuretics in certain predisposed approximately 1500 mL of volume was given [19] , while individuals might have affected the results. in our study the amount was somewhat less at 1180 mL.
The pathogenesis of contrast-induced renal dysfuncBoth studies used nonionic, low osmolality contrast dye, tion is incompletely understood [22] . There is some evibut patients in our study received a slightly higher mean dence that either renal vasoconstriction and/or tubular dose (81.6 vs. 75 mL). In addition, as opposed to the toxic damage may play a role. Contrast infusion causes intravenous injection of dye in CT imaging, in cardiac a brief and transient increase in renal plasma flow and angiography injection is directly interarterial. On balglomerular filtration rate, followed almost immediately ance, it would appear that subjects in our study probably by a sustained decrease in both of these parameters had a somewhat higher net risk for developing contrast [23, 24] . In parallel there is a sustained increase in renal nephropathy. However, acute renal dysfunction develvascular resistance. These hemodynamic changes are oped in a similar proportion of placebo group subjects caused by release of vasoactive mediators in the kidney. in both studies (22 vs. 21%), suggesting a counterbalanc-
The best evidence to date is for the role of endothelin ing of risk effects.
in driving these processes [25] [26] [27] . However, a clinical Another difference between our study and that of trial of an endothelin receptor antagonist failed to demTepel et al was in the protocol for NAC administration onstrate a protective effect [18] . Moreover, a correlation [19] . Tepel et al gave the drug at 600 mg orally twice between renal vasoconstriction and the development of renal failure has not been found in humans [7] . daily, the day before and the day of contrast infusion,
